<DOC>
	<DOC>NCT00365924</DOC>
	<brief_summary>This methodology trial will be conducted in patients with osteoporosis and will measure the changes in bone quality parameters, micro- and macroarchitecture, bone biomarkers and bone density following therapy with the approved drug, Forteo.</brief_summary>
	<brief_title>A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal women with osteoporosis Any therapies or products affecting bone turnover within 12 months of Screening. Bisphosphonate treatment &gt;1 month in total duration at any time in the past. In addition, patients must be bisphosphonatetreatmentfree for at least 12 months prior to Screening.</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>12 month therapy with postmenopausal women with osteoporosis to examine changes in bone quality parameters</keyword>
</DOC>